Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 23, 2023

SELL
$2.0 - $3.2 $27,056 - $43,289
-13,528 Reduced 50.14%
13,451 $27,000
Q1 2023

May 15, 2023

BUY
$1.43 - $3.3 $38,579 - $89,030
26,979 New
26,979 $67,000
Q4 2020

Feb 12, 2021

BUY
$3.99 - $17.73 $99,590 - $442,540
24,960 New
24,960 $116,000
Q1 2020

May 11, 2020

SELL
$4.01 - $8.88 $82,381 - $182,430
-20,544 Closed
0 $0
Q4 2019

Feb 12, 2020

SELL
$3.62 - $4.29 $38,715 - $45,881
-10,695 Reduced 34.24%
20,544 $88,000
Q3 2019

Nov 14, 2019

SELL
$3.54 - $4.48 $59,256 - $74,990
-16,739 Reduced 34.89%
31,239 $121,000
Q2 2019

Aug 20, 2019

BUY
$3.59 - $4.3 $116,330 - $139,337
32,404 Added 208.06%
47,978 $190,000
Q1 2019

May 15, 2019

BUY
$3.37 - $4.34 $52,484 - $67,591
15,574 New
15,574 $68,000

Others Institutions Holding BCLI

About BRAINSTORM CELL THERAPEUTICS INC.


  • Ticker BCLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,486,200
  • Market Cap $39.4M
  • Description
  • Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem ...
More about BCLI
Track This Portfolio

Track Wolverine Trading, LLC Portfolio

Follow Wolverine Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Trading, LLC with notifications on news.